MindMed reports results for Q1 2022. Progress on clinical trials. Used $12.9 million cash in previous quarter. Cash balance of $120.5 million as of March 31, 2022.
MindMed reports results for Q1 2022. Progress on clinical trials. Used $12.9 million cash in previous quarter. Cash balance of $120.5 million as of March 31, 2022.
MindMed announces an at-the-market financing with a prospectus authorizing share sales of up to $100,000,000. Not open to Canadian investors.
Delic Holdings announces that it will miss its deadline under Canadian Securities Law to file its audited financial results. As a results, a Management Cease Trade Order (MCTO) has been issued.
Red Light Holland announces successfully importing its psilocybin microdose packs from the Netherlands into Canada.
Numinus Wellness announces Health Canada approval of its application to use psilocybin-assisted therapy for treatment-resistant depression (TRD).
atai Life Sciences reports Q1 for 2022: clinical trials advancing and cash position of $335 million.
A new partnership between the U.S. Veterans Administration and Delic Holdings is ushering in a new era for PTSD treatment in the U.S. military.
MindMed announces it will host a webinar on substance abuse disorders and withdrawal management that includes prominent experts in this field.
Revitalist Lifestyle and Wellness reports strong month-over-month and year-over-year revenue gains from its ketamine clinic operations.
Delic Holdings subsidiary, Ketamine Wellness Centers (KWC) announces a partnership with the Veterans Administration to provide ketamine-assisted therapy for veterans with PTSD.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now